ClinicalTrials.gg
CompletedNCT05469919Updated Aug 2, 2024

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

A Phase 1 interventional study of Ceralasertib in Advanced Solid Malignancies, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ceralasertib in Japanese patients with advanced solid malignancies. Cycle 0 duration is 4 days and each cycle from Cycle 1 has a duration of 28 days.

Read the detailed description

\<Objectives>

Primary Objective:

To investigate the safety and tolerability of ceralasertib in Japanese patients with advanced solid malignancies

Secondary Objective:

To assess the anti-tumor activity and efficacy of ceralasertib. To characterize the first- and multiple-dose pharmacokinetics of ceralasertib.

Exploratory Objective:

To conduct exploratory research into factors that may be predictive of response or may influence the progression of cancer and/or response (efficacy, tolerability, or safety) to ceralasertib.

\<Overall design> This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ceralasertib in Japanese patients with advanced solid malignancies. Cycle 0 duration is 4 days and each cycle from Cycle 1 has a duration of 28 days.

Ceralasertib 240 mg monotherapy in cohort 1 will be orally administered as a single dose at Cycle 0 (Cycle 0 duration is 4 days) Day 1 and twice daily from Day 1 to Day 7 of each 28-day cycle (from Cycle 1). Ceralasertib monotherapy of 160 mg will be orally administered as a single dose at Cycle 0 (Cycle 0 duration is 4 days) Day 1 and twice daily from Day 1 to Day 14 of each 28-day cycle (from Cycle 1), respectively, in cohort 2. Each patient will undergo an DLT evaluation period (Cycle 0 and 1) to have the DLT of ceralasertib determined. Patients will continue with the treatment until disease progression, unacceptable toxicity, or withdrawal from the study.

A minimum of 3 and a maximum of 6 evaluable patients will be enrolled in each cohort ("rolling 6 design"). If no DLT is observed in 3-6 evaluable patients or only 1 DLT is observed in 6 evaluable patients in the current cohort, then transition to the following cohort may occur. If 2 or more patients experience a DLT in each cohort of up to 6 evaluable patients, irrespective of the number of patients enrolled, the dose will be considered not tolerated and recruitment to the current cohort and transition to the following cohort will cease. At the completion of the current cohort, a decision will be made to begin the following cohort based on the SRC review. If no DLT is observed in a 3-6 evaluable patients or only 1 DLT is observed in 6 evaluable patients in a dose setting, the dose is considered tolerated.

Other doses/schedules/combination or cohort expansion may be implemented based on emerging data and the SRC review.

02

Conditions studied

  • Advanced Solid Malignancies

Keywords

  • Phase 1
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Advanced solid malignancies
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  1. Signed written .
  2. At least 18 years of age at the time of signing the ICF.
  3. Histological or cytological confirmation of a solid, malignant tumor that is to standard therapies or for which no standard therapies exist.

    Measurable or non- according to version 1.1.

  4. /World Health Organization (ECOG/WHO) performance status of 0 to 1 with no deterioration between screening and the first dose of the study treatment, and a minimum of 12 weeks
  5. Body weight >30 kg and no cancer-associated cachexia (e.g., [CTCAE] Grade 2 or worse weight loss over the past 3 months).

Major Exclusion Criteria:

  1. History of another primary except for:

    • Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of the study drug and of low potential risk for recurrence
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease
  2. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting the study treatment, with the exception of alopecia and chemotherapy-related peripheral neuropathy.
  3. Presence of life-threatening visceral disease, as judged by the investigator, uncontrolled central nervous system (CNS) metastatic disease. Patients with spinal cord compression and/or may be enrolled if definitively treated (e.g., surgery or radiotherapy) and stable off for at least 4 weeks prior to start of the study treatment.
  4. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), (known positive hepatitis B virus [HBV], surface antigen [HBsAg] result), , or (positive HIV 1/2 antibodies).

    Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if the polymerase chain reaction is negative for HCV RNA.

  5. Diagnosis of ataxia telangiectasia.
  6. Refractory nausea and vomiting, chronic gastrointestinal diseases, or previous significant stomach/bowel resection, with sequelae that would preclude adequate dissolution/absorption of ceralasertib. Partial gastrectomy with preservation of gastric pyloric function and partial resection of the large intestine can be eligible, but inclusion of patients with gastric pylorus resection or patients with duodenum, jejunum or ileum resection requires discussion with the sponsor.
  7. Past medical history of interstitial lung disease (ILD) / pneumonitis requiring steroid treatment or any evidence of clinically active ILD / pneumonitis or potential ILD / pneumonitis which is not excluded by the screening test.
  8. Treatment with any of the following:

    1. Any medicinal product or other systemic anticancer treatment within 4 weeks prior to the first dose of the study treatment, except for immunotherapy or antibody therapy which has five-fold half-life >4 weeks is within 8 weeks.

      Note: androgen-deprivation therapy is permitted for patients with prostate cancer

    2. The potent inducers or inhibitors of within 2 weeks of the first dose of the study treatment; except for St. John's wort, which is 3 weeks.
    3. Prior exposure to an ATR inhibitor.
    4. Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of the study treatment
    5. Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of the study treatment.
  9. Participation in any clinical research study involving treatment with any investigational drug, radiotherapy or surgery, except for the non-treatment phases of these studies, e.g., follow-up phase.
  10. History of to active or inactive of ceralasertib or drugs with a similar chemical structure or class to ceralasertib.
  11. Patient has any of the following cardiac criteria:

    1. Mean corrected by Fridericia's formula (QTcF) for heart rate ≥470 ms calculated from ECGs.
    2. Any clinically important abnormalities in rhythm, conduction, or morphology of resting , e.g., complete left bundle branch block, third degree heart block, second degree heart block, first degree heart block.
    3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval.
    4. Patients with uncontrolled hypertension-blood pressure (BP) ≥150/95 mmHg despite medical therapy.
    5. Patients with relative hypotension (BP\<100/60 mmHg) or clinically relevant orthostatic hypotension, including a fall in blood pressure of >20 mmHg.
    6. Unstable atrial fibrillation or unstable cardiac arrhythmia with a ventricular rate >100 bpm on an ECG at rest.
    7. Symptomatic heart failure- Grade II to Grade IV.
    8. Prior or current cardiomyopathy.
    9. Severe valvular heart disease.
    10. Uncontrolled angina (Canadian Cardiovascular Society Grade II to Grade IV despite medical therapy) or acute coronary syndrome within 6 months prior to screening.
    11. Patients at risk of brain perfusion problems, e.g., carotid stenosis. Stroke or in the last 6 months prior to screening.
  12. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values. Note that growth factor or blood transfusion support to solely meet the criteria is prohibited for 14 days prior to the screening test unless otherwise noted:

    1. [ANC] \<1.5 × 109/L.
    2. count \<100 × 109/L.
    3. \<9 g/dL with no blood transfusions (packed red blood cells) in the past 28 days.
    4. Persisting (>4 weeks) severe pancytopenia due to previous therapy rather than disease (ANC \<1.5 × 109/L or platelets \<100 × 109/L).
    5. (ALT) >2.5 × the (ULN).
    6. Aspartate aminotransferase (AST) >2.5 × ULN.
    7. Total (TBL) >1.5 × ULN or >3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia).
    8. Alkaline phosphatase (ALP) >2.5 × ULN (and liver disease unrelated to the tumor).

      Patients with elevated ALP due to tumor related bone metastases or liver metastases will be eligible.

    9. \<45 mL/min calculated by Cockcroft-Gault equation
    10. Haematuria: +++ on microscopy or dipstick.
    11. ≥1.5 or other evidence of impaired hepatic synthesis function.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ceralasertib monotherapy

    This is a sequential group treatment/dose-escalation study with 2 cohorts with no masking.

    Drug: Ceralasertib

Interventions

06

What researchers measure

Primary outcomes

  1. The number of subjects with dose-limiting toxicity, as defined in the protocol.

    Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optional therapeutic intervention, meets protocol-defined criteria.

    Time frame: From the first dose of study treatment Up to and including the end of cycle 1(each cycle is 28 days).

  2. Safety and tolerability in terms of adverse events

    Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs, electrocardiograms (ECGs), safety and laboratory parameters

    Time frame: From the first dose of study treatment until 28 days after the last dose.

Secondary outcomes

  1. Overall response rate

    Antitumor activity by evaluation of tumor response assessments using RECIST 1.1

    Time frame: At screening and Every 8 weeks ±1 week relative to the start of therapy (Cycle 1 Day 1, each cycle is 28days) until objective disease progression as defined by RECIST version 1.1

  2. Duration of Response

    Antitumor activity by evaluation of tumor response assessments using RECIST 1.1

    Time frame: At screening and Every 8 weeks ±1 week relative to the start of therapy (Cycle 1 Day 1, each cycle is 28 days) until objective disease progression as defined by RECIST version 1.1

  3. Percentage Change in Tumour Size

    Antitumor activity by evaluation of tumor response assessments using RECIST 1.1

    Time frame: At screening and Every 8 weeks ±1 week relative to the start of therapy (Cycle 1 Day 1, each cycle is 28 days) until objective disease progression as defined by RECIST version 1.1

  4. Progression Free Survival

    Antitumor activity by evaluation of tumor response assessments using RECIST 1.1

    Time frame: From start of treatment until the date of objective disease progression or death. (approximately 6 months).

  5. Plasma ceralasertib concentration(Cmax)

    Observed PK parameters of ceralasertib

    Time frame: Cycle 0 Day1 to Day4, Cycle1 Day1 and Cycle 1 Day 7 or Day 8. At the end of Cycle1(each cycle is 28 days)

  6. Area under the plasma concentration versus time curve(AUC)

    Observed PK parameters of ceralasertib.

    Time frame: Cycle 0 Day1 to Day4, Cycle1 Day1 and Cycle1 Day7 or Day8. At the end of Cycle1(each cycle is 28 days)

07

Study locations

1 site
  • Research Site
    Chuo-ku, 104-0045, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Aug 2023, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2022
First posted
Jul 22, 2022
StartActual
Jun 9, 2022
Primary completionActual
Aug 17, 2023
CompletionActual
Mar 12, 2024
Last update
Aug 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05469919
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Jun 9, 2022
Primary completion
Aug 17, 2023
Completion
Mar 12, 2024
Last update
Aug 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceralasertib

Start the discussion